张军教授，博士生导师，长江（特岗）学者，国家高层次人才特殊支持计划领军人才。长期从事疫苗、诊断研究。曾获全国创新争先奖、国家技术发明二等奖、国家科技进步二等奖、中国青年科学家奖、求是杰出科技成就集体奖、中国青年五四奖章等。在《新英格兰医学杂志》《柳叶刀》等刊物发表论文100余篇。做为主要负责人之一参与研发的第一个国产HPV疫苗、世界上第一个戊型肝炎疫苗和一批诊断试剂均已在多个国家获批上市。
主要学术兼职
中华预防医学会流行病学分会常委，中华预防医学会疫苗临床研究专委会常委，中华预防医学会卫生应急分会常委，中国医师协会公共卫生医师分会常委，中国疫苗行业协会疫苗临床研究分会副主委。
Zhang, Jun
Professor,
Dean,
School of Public Health,
Deputy Director,
National Institute of Diagnostics and Vaccine Development in infectious disease,
Xiamen University,
Xiamen, Fujian, 361005
P.R.China
Email: zhangj@xmu.edu.cn
http://www.researcherid.com/rid/G-4598-2010
https://orcid.org/0000-0002-6601-9180
Professor Jun Zhang’s research interests focus on the virology, immunology and epidemiology of human pathogens. As one of the leading scientists, he is deeply involved in the innovation and translation of hepatitis E vaccine, HPV vaccine, COVID-19 vaccine and many immunologic diagnostic reagents against infectious pathogens. Among them, Hepatitis E vaccine (Hecolin) and HPV 16/18 bivalent vaccine (Cecolin) had been launched in China; the nine-valent HPV vaccine are under Phase III clinical trial. He had published > 100 papers in peer reviewed journals.
EDUCATION
1989-1994 Shanghai Medical University, B.A Preventive Medicine
1994‑1997 Shanghai Medical University, M.S Epidemiology
PROFESSIONAL POSITIONS
2021-Date Professor, Dean, School of Public Health, Xiamen University
2011-2021 Professor, Associate Dean, School of Public Health, Xiamen University
2006-Date Professor, Deputy Director, National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University
2002-2006 Associate Professor, School of Life Sciences, Xiamen University
1997-2002 Research assistant, School of Life Sciences, Xiamen University
SELECTIVE PUBLICATIONS
> 100 peer-reviewed publications
1. Huang S, Zhang X,…Zhang J*, et al.Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.2024;403(10429):813-823
2. Zhang J#, Zhang XF, et al. Long-Term Efficacy of a Hepatitis E Vaccine. N Engl J Med. 2015;372(10):914-22
3. Zhu FC, Zhang J#, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895-902
4. Pan HX, Qiu LX,…Zhang J*, et al. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial. Lancet Infect Dis. 2024;S1473-3099(24)00159-2
5. Zhu FC,Zhong GH,…Zhang J*,et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. Lancet Infect Dis. 2023;23(11):1313-1322.
6. Zhu FC, Huang SJ,…Zhang J*, et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(12):1075-1088
7. Zhu FC, Zhuang CL,…Zhang J*, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749-60
8. Zhao FH, Wu T,…Zhang J*, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022;22(12):1756-1768.
9. Huang Y, Tang J, …Jun Zhang*, et al. Pre-existing maternal IgG antibodies as a protective factor against congenital cytomegalovirus infection: A mother-child prospective cohort study. EBioMedicine. 2022 Mar;77:103885. doi: 10.1016/j.ebiom.2022.103885.
10. Zhaojun Mo, Shoujie Huang, …Jun Zhang*, et al. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial. The Lancet Regional Health-Western Pacific. 2023;34:100707.
11. Kai Chu, Zhaofeng Bi, …Jun Zhang*, et al. Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial. The Lancet Regional Health-Western Pacific. 2023;34:100731.
12. Yao X, Chen W, …Jun Zhang*, et al. Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. The Lancet Regional Health – Western Pacific.2021.13:100196.
13. Huang Y, Wang H, …Jun Zhang*, et al. Comparison of detection strategies for screening and confirming congenital cytomegalovirus infection in newborns in a highly seroprevalent population: a mother-child cohort study. The Lancet Regional Health – Western Pacific.2021.12:100182.
14. Wu Y, Wang S, …Jun Zhang*, et al. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19. Cell Host Microbe. 2022(1931-3128)
15. Wu Y, Huang X, …Jun Zhang*, et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Science Translational Medicine. 2021.20:eabg1143.
16. Liang Zhang, Yao Jiang, …Jun Zhang*, et al. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nature Communications. 2023;14(1):4117.
17. Wang W, Pan D, …Jun Zhang*, et al. Development of a skin- and neuro-attenuated live vaccine for varicella. Nature Communications. 2022;13(1):824.
18. Xiong H, Sun H, …Jun Zhang*, et al. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proceedings of the National Academy of Sciences. 2022;119(34):e2204256119.
19. Zhang TY, …, Zhang J*, et al.. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020, 69(2):343-354.
20. Wei F, …, Zhang J*, Xia N. Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. Clin Infect Dis 2020, 70(1): 82-89.
21. Zhao J, …, Zhang J*, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020:ciaa344.
22. Lou B, …, Zhang J*, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020,56(2):2000763. doi: 10.1183/13993003.00763-2020.
23. Ji MF, …, Zhang J*, Cao SM*. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019, 30(10):1630-1637.
24. Huang CH, Y…, Zhang J*, Xia NS*. Influence of Mutations in Hepatitis B Virus Surface Protein on Viral Antigenicity and Phenotype in Occult HBV Strains from Blood Donors. J Hepatol. 2012,57(4):720-9.
25. Qiao YL*, …Zhang J*, Xia NS*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. J Natl Cancer Inst, 2020, 112(2):145-153.
